AC
RIGL icon

Armistice Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Armistice Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.4M Buy
1,672,000
+392,000
+31% +$12.1M 0.8% 18
2026
Q1 		$34.6M Buy
1,280,000
+444,000
+53% +$14.9M 0.62% 26
2025
Q4 		$35.8M Buy
836,000
+112,000
+15% +$4.22M 0.43% 40
2025
Q3 		$20.5M Sell
724,000
-876,000
-55% -$26.2M 0.3% 51
2025
Q2 		$30M Buy
1,600,000
+84,000
+6% +$1.59M 0.52% 31
2025
Q1 		$27.3M Buy
1,516,000
+364,000
+32% +$7.39M 0.41% 51
2024
Q4 		$19.4M Sell
1,152,000
-384,000
-25% -$7.36M 0.26% 78
2024
Q3 		$24.9M Sell
1,536,000
-88,000
-5% -$1.03M 0.4% 46
2024
Q2 		$13.3M Buy
1,624,000
+88,000
+6% +$921K 0.17% 83
2024
Q1 		$22.7M Sell
1,536,000
-174,000
-10% -$2.34M 0.3% 55
2023
Q4 		$24.8M Sell
1,710,000
-3,600
-0.2% -$36.8K 0.34% 52
2023
Q3 		$18.5M Buy
1,713,600
+3,600
+0.2% +$43.3K 0.28% 62
2023
Q2 		$22.1M Buy
1,710,000
+7,600
+0.4% +$103K 0.32% 60
2023
Q1 		$22.5M Buy
1,702,400
+6,800
+0.4% +$108K 0.32% 58
2022
Q4 		$25.4M Buy
1,695,600
+1,350,313
+391% +$12.4M 0.44% 45
2022
Q3 		$4.07M Buy
+345,287
New +$4.67M 0.07% 103
2020
Q3 		– Sell
-52,270
Closed -$957K – 118
2020
Q2 		$957K Buy
+52,270
New +$940K 0.04% 78

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Armistice Capital's RIGL Position: Q2 2026 in Review

Armistice Capital increased its Rigel Pharmaceuticals (RIGL) stake by 31% in Q2 2026, buying an estimated $12.1M and bringing the position to 1,672,000 shares worth $65.4M. The position accounts for 0.8% of the portfolio, ranked #18.

Armistice Capital first reported a position in RIGL in Q2 2020 and has held it in 17 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Armistice Capital held 1,672,000 shares of Rigel Pharmaceuticals worth $65.4M as of Q2 2026.
  • Armistice Capital bought 392,000 Rigel Pharmaceuticals shares in Q2 2026, an estimated $12.1M.
  • Rigel Pharmaceuticals made up 0.8% of Armistice Capital's portfolio in Q2 2026, its #18 holding.
  • Armistice Capital first reported a position in Rigel Pharmaceuticals in Q2 2020 and has held it in 17 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.